Affiris GmbH of Vienna, Austria said its Alzheimer's vaccine entered clinical trials, triggering a key milestone in its Euro 8.5 million venture capital finance agreement with Munich-based MIG-Fonds in April 2006.
Up to 24 Alzheimer's patients are to be vaccinated, with the aim of this initial phase I trial being to demonstrate safety. Patients will be vaccinated four times over a period of three months, and the safety and suitability of the vaccine will be analysed over six months.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.